EAM
LSBPW

Exos Asset Management’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Exos Asset Management’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,000
Closed -$4.4K – 96
2024
Q2 		$4.4K Hold
50,000
– – 0.01% 115
2024
Q1 		$3.58K Buy
+50,000
New +$2.79K ﹤0.01% 154

Other funds holding LSBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
BP
BFAM Partners Northpoint, Hong Kong, Hong Kong $44K AUM 8.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Exos Asset Management's LSBPW Position: Q3 2024 in Review

Exos Asset Management sold out of LakeShore Biopharma Warrants (LSBPW) in Q3 2024, closing a stake of 50,000 shares — an estimated $4.4K sold.

Exos Asset Management first reported a position in LSBPW in Q1 2024 and held it in 2 quarters. The position peaked at $4.4K in Q2 2024. 21 funds tracked by Wall St. Rank hold LSBPW as of Q3 2024.

  • Exos Asset Management reported no remaining LakeShore Biopharma Warrants position as of Q3 2024 after selling out during the quarter.
  • Exos Asset Management sold 50,000 LakeShore Biopharma Warrants shares in Q3 2024, an estimated $4.4K.
  • Exos Asset Management first reported a position in LakeShore Biopharma Warrants in Q1 2024 and held it in 2 quarters.
  • Exos Asset Management's LakeShore Biopharma Warrants position peaked at $4.4K in Q2 2024.
  • 21 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q3 2024.

Based on Exos Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.